Section III — The Evidence
PT-141 Research: From Rat Solicitation to Two Phase 3 Trials
The human evidence weighed honestly — the approved desire indication in women, the early investigational record in men, and the critical re-analyses that say the benefit is real but small.
Before the details
PT-141 (bremelanotide) has a fuller human evidence base than most compounds in this register — and a more sharply bounded one. Two large Phase 3 trials, a 52-week extension, mechanistic brain imaging, and metabolic studies all exist. They support one approved use: low sexual desire in premenopausal women. The famous male, erectile use never reached approval and rests on early-phase work, some of it now disputed. So the research record is rich, real, and narrow — and this page keeps the approved evidence and the off-label evidence plainly apart.
The foundation: central melanocortin pharmacology
The earliest pivotal work established the class. Systemic PT-141, a synthetic alpha-MSH analogue and agonist at melanocortin MC3R/MC4R receptors, produced penile erections in rats and nonhuman primates, activated hypothalamic neurons (increased c-Fos, a marker of neuronal firing), and produced rapid, dose-dependent erectile activity in men with erectile dysfunction [1]. That paper named the mechanism — central, melanocortin-mediated — and set the agenda for everything that followed [1].
The female-desire thread opened in parallel. In female rats, PT-141 selectively facilitated solicitational sexual behaviour without affecting lordosis, pacing, or motor activity — the first pharmacological agent reported to act on appetitive female sexual behaviour, and the preclinical seed of the eventual human indication [2]. A preclinical review consolidated the central-nervous-system evidence that melanocortin activation modulates appetitive female sexual behaviour [8], and a class review situated bremelanotide within melanocortin pharmacology for male and female sexual dysfunction [9].
PT-141 for Women: The Approved HSDD Indication
The case for PT-141 for women rests on two identical Phase 3 randomized controlled trials, known as RECONNECT. Across 1,267 premenopausal women with HSDD, bremelanotide 1.75 mg subcutaneous as-needed produced a statistically significant improvement in sexual desire (integrated FSFI-desire +0.35, P<.001) and reduced desire-related distress (integrated FSDS-DAO item 13 -0.33, P<.001) versus placebo over 24 weeks [3]. FSFI and FSDS-DAO are the standard validated questionnaires trials use to score sexual desire and the distress that low desire causes; both coprimary endpoints were met in both trials [3].
The long view held. In the 52-week open-label extension, into which 684 women enrolled, no new safety signals emerged and the desire improvements were sustained; the most common drug-related adverse events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. A patient-experience analysis documented how treated women perceived the benefit and the tolerability, giving the trial numbers a lived context [13]. On the strength of this record, bremelanotide was approved in June 2019 for acquired, generalized HSDD in premenopausal women — the compound's single licensed indication [11] [12].
What benefits did the PT-141 trials measure?
The PT-141 benefits measured in the pivotal trials were specific and modest: an integrated FSFI-desire improvement of +0.35 and an integrated FSDS-DAO item-13 (distress about low desire) change of -0.33 versus placebo, both statistically significant at P<.001 over 24 weeks [3]. The mechanistic fMRI study added that MC4R agonism raised desire for up to 24 hours and shifted central processing of erotic stimuli [5]. These are real, reproducible endpoints in the approved population — and, as the next section records, their clinical size has been openly contested [3] [5].
The honest caveat: the effect is real but small
An editorial digest does not bury its strongest counter-evidence. Critical re-analyses by Spielmans (2021, 2024) argue that the trial effects on desire and distress, while statistically significant, are small, and they question the clinical meaningfulness of the endpoints and the way benefit was framed [3] [4]. The point is not that the trials failed — both met their coprimary endpoints — but that 'statistically significant' and 'clinically large' are different claims, and only the first is firmly established here [3].
The regulatory path had setbacks of its own before approval, and the benefit-risk balance has been appraised expertly and unsentimentally for premenopausal women — efficacy modest, tolerability non-trivial, place in therapy real but bounded [16]. That is the record as it stands, stated without varnish [16].
PT-141 for Men: Off-Label and Investigational Erectile Research
The history of PT-141 for men is older than its approval and far less settled. The earliest pivotal pharmacology showed rapid, dose-dependent erectile activity in men with erectile dysfunction, and early development tested an intranasal route, with a statistically significant erectile response reported above roughly 7 mg [1]. For a time, male erectile dysfunction looked like the lead indication.
It is not an approved use. Despite the Phase 2 erectile-dysfunction data, bremelanotide is approved only for premenopausal women with HSDD; all male use is off-label and the supporting evidence is early-phase, not confirmatory [11]. The record here also carries a formal blemish: a 2023 Expression of Concern was issued for a 2008 Safarinejad & Hosseini erectile-dysfunction salvage study, and its findings should be treated as disputed [11]. Material sold as 'PT-141 research chemical' for such use is unregulated laboratory material, not the approved medicine [11]. The male/erectile use is, in short, investigational — interesting history, not established therapy.
What the reviews and recent work add
The secondary literature is consistent on the shape of the compound. A neurology-readership review covered mechanism, efficacy, and clinical considerations for female HSDD [7]; a neurobiology synthesis connected MC4R activation in hypothalamic and limbic circuits to female sexual desire [10]; an approval-era pharmacotherapy review summarized the RECONNECT data, the 1.75 mg dosing, and the adverse-event profile [12].
The most recent primary work is a careful corrective. In female Syrian hamsters (2025), MC3R/MC4R messenger RNA concentrated in ventral-tegmental-area dopamine neurons, but bremelanotide changed neither that expression nor sexual reward in a conditioned-place-preference test — a nuanced, partly negative finding suggesting the drug does not act on the mesolimbic reward circuit even as it acts on desire elsewhere [14]. Recent research, in other words, is sharpening the mechanism rather than widening the claims [14].
That is the fitting note to close on. The strongest threads in this literature run inward, toward a more exact account of where and how a central melanocortin signal shapes desire — the hypothalamic circuit, the dopaminergic engagement, the up-to-24-hour window seen in imaging [5]. The threads that run outward, toward new populations and new uses, remain thin: the male and erectile evidence is early-phase and partly disputed, and the single approved indication has not been joined by another [1] [11]. A reader leaving this page with one sentence should take that asymmetry — deep where it is approved, shallow everywhere else — as the honest shape of the record.